



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,438	01/20/2006	Bertrand Cosson	0510-1133	2184
<small>465</small> YOUNG & THOMPSON 209 Madison Street Suite 500 ALEXANDRIA, VA 22314			<small>7590</small> EXAMINER AUDET, MAURY A	
			ART UNIT 1654	PAPER NUMBER
			MAIL DATE 09/29/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/565,438

Applicant(s)

COSSON ET AL.

Examiner

MAURY AUDET

Art Unit

1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 1/20/06.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) 1-6, 9-36 and 38-40 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 7, 8, and 37 is/are rejected.
- 7) ☒ Claim(s) 7, 8 and 37 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 20 January 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 4/20/06
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

SUPPLEMENTAL DETAILED ACTION

The present action is sent to correct the response period from inadvertently being made 1 month, to 3 months. The Examiner apologizes to Applicant for the oversight.

Election/Restrictions

As stated in the restriction requirement under 35 U.S.C. 121 and 372, the groupings include, in accordance with 37 CFR 1.499:

- I. Claims 1-6, drawn to a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1.
- II. Claims 7-8 and 37, drawn to a fusion polypeptide specifically capable of inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein.
- III. Claims 9-17, and 29, drawn to a nucleic acid comprising a polynucleotide coding for a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 or fusion polypeptide comprising the same OR a kit therefore OR a control system of the translation of a target polynucleotide of interest comprising a fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins,

characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein.

IV. Claims 18, 22-23, 31-33, and 38-40, drawn to a recombinant cloning or expression vector comprising a nucleic acid comprising a polynucleotide coding for a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 or fusion polypeptide comprising the same OR a kit for the control thereof OR a control system comprising a recombinant expression vector comprising a nucleic acid of the translation of a target polynucleotide of interest comprising a fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein.

V. Claims 24-26, drawn to a prokaryotic or eukaryotic host cell comprising a nucleic acid of the translation of a target polynucleotide of interest comprising a fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein OR control system thereof.

VI. Claims 27-28, drawn to a method for the in vitro control of the translation of a target polynucleotide of interest comprising a fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein.

VII. Claims 34-36, drawn to a method for the control of the translation of a target polynucleotide of interest comprising providing a control system comprising a first nucleic acid and a second nucleic acid comprising a fusion polypeptide specifically inhibiting the translation of a target polynucleotide of interest, characterised in that said polypeptide comprises a peptide inhibitor of the translation of proteins, characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1 fused with an RNA binding protein.

Applicant's election of Group II, claims 7-8 and 37, as drawn to the elected peptides of SEQ ID NOS: 5-6, in the reply filed on 10/6/08, is acknowledged. Since the Examiner is willing to search/examine both SEQ ID NOS: 5-6, Applicant's only substantive argument for traversal (e.g. that these two peptides should be searched, and can be without an undue burden, which the Examiner concurs) is moot. Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claim Objections

Claims 7-8 and 37 are objected to because of the following informalities:

the claims have not been amended commensurate in scope with the elected invention of peptides **SEQ ID NOS: 5-6**.

Namely, Applicant must amend the Group II invention to:

A fusion polypeptide specifically capable of inhibiting the translation of a target polynucleotide of interest, wherein said polypeptide is selected from the group consisting of SEQ ID NOS: 5-6, fused with an RNA binding protein (e.g. MS2CP, N, IRP and U1A; MS2CP).

[As opposed to the originally claimed, nonelected genus which must be amended thereto, and the following deleted “characterised in that its length is up to 250 amino acids and in that it comprises an amino acid sequence possessing at least 85% identity with the amino acid sequence of SEQ ID NO: 1”.]

Were the claims so amended, and to include the 4 RNA binding protein species of **MS2CP, N, IRP and U1A; MS2CP**, the application would likely receive favorable consideration (see 112 1st Written Description rejection below).

Appropriate correction is required.

NOTE: Applicant may wish to begin claims 7-8 and 37, with the term “A”, for grammatical fluidity.

Claim Rejections - 35 USC § 112 1st Written Description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 7-8 and 37 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a “written description” rejection, rather than an enablement rejection under 35 U.S.C. 112, first paragraph. Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 “Written Description” Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

Vas-Cath Inc. V. Mahurka, 19 USPQ2d 1111, states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention, for purposes of the “written description” inquiry, is *whatever is now claimed*” (see page 1117).

The claimed invention is primarily drawn to a **A fusion polypeptide specifically capable of inhibiting the translation of a target polynucleotide of interest, wherein said polypeptide is selected from the group consisting of SEQ ID NOS: 5-6, fused with an RNA binding protein (e.g. MS2CP, N, IRP and U1A; MS2CP).**

One of skill in the art would not recognize from the disclosure that the Applicant was in possession of the claimed genus of any RNA binding protein, as capable of conjugation to the

Art Unit: 1654

elected SEQ ID NOS: 5-6, in order to have possession of the "fusion peptides" as claimed. The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed" (see *Vas-Cath* at page 1116). Specifically, the specification was only found to generally discuss the 'concept' of the invention:

[0105] According to another feature, the invention relates to fusion polypeptides capable of inhibiting specifically the translation of a target polynucleotide of interest to the corresponding protein, such a fusion polypeptide comprising a peptide inhibitor of the translation of proteins such as previously defined in the description, said peptide inhibitor being fused with an RNA binding protein specifically recognizing a target nucleotide site of the messenger RNA which is targeted.

[0134] According to another feature, the invention relates to fusions between peptide and oligonucleotide capable of inhibiting specifically the translation of a target polynucleotide of interest into the corresponding protein. Such a fusion molecule comprising a peptide inhibitor of the translation of proteins such as previously defined in the description, said peptide inhibitor being fused with an oligonucleotide specifically recognizing a target nucleotide site of an mRNA which is the target. **An example of this type of oligonucleotide is Aptastruc described in the PCT application N.sup.o PCT/FR 95/01036.**

[0158] As can be understood, the entire potentiality of the control system of the translation of proteins according to the invention is attained when the expression of the peptide inhibitor-RNA binding protein fusion polypeptide is inducible: thus, repression of the synthesis of the said fusion polypeptide will allow the translation of the target polynucleotide of interest into the corresponding protein, whereas activation of the expression of the fusion polypeptide will inhibit the translation of the target polynucleotide of interest into the corresponding protein.

The specification and Claim 8 only describe/claim (claim 8) 4 specific RNA binding proteins species: MS2CP, N, IRP and U1A; MS2CP, being the single RNA binding peptide species, with no indication of overlapping sequence therein or generalizability as to an RNA

Art Unit: 1654

binding protein that will carry out the invention or of reference to a genus list of such peptides (See specification p. 16, Table 1):

Table 1 : Preferred binding proteins

Binding protein	Reference
MS2	J.Coller, N.Gray, M.Wickens, Genes Dev.12 (1998) 3226-3235. Witherell, G., J. Gott, and O. Uhlenbeck. 1991. Specific interaction between RNA phage coat proteins and RNA. <i>Prog. Nucleic Acids Res. Mol. Biol.</i> 40 : 185-220
N	E.De Gregorio, T.Preiss, M.W. Hentze, EMBO J.18 (1999) 4865-4874. Tan, R. & Frankel, A. D. (1994) <i>Biochemistry</i> 33 , 14579-14585
IRP	E.De Gregorio, J.Baron, T.Preiss, M.Hentze, RNA 7 (2001)106-113. Hentze MW; Kuhne LC. <i>Proc Natl Acad Sci U S A.</i> 1996 Aug 6;93(16):8175-82. Review. PMID: 8710843
U1A	A.S. Brodsky, P.A. Silver, RNA 6 (2000) 1737-1749.

The other section of the specification bearing the same include:

[0007] In order to test the biological activity of the different proteins capable of acting on the various post-transcriptional steps of the expression of the genes, i.e. on the different aspects of the metabolism of the messenger RNAs mentioned above, it has been suggested, in the state of the art, that the protein whose function is tested be fused with an RNA binding protein of known specificity, such as the protein MS2CP. The activity of the fusion protein (test protein-RNA binding protein) is tested on a DNA reporter construction coding for a messenger RNA comprising (i) the target nucleotide motif of the RNA binding protein and (ii) an open reading frame encoding a reporter protein, like luciferase or beta-globin (COLLER et al., 2002, PCT application N.sup.o WO 99/60.408).

[0023] FIG. 1 illustrates the mode of action of a fusion polypeptide according to the invention comprising the peptide inhibitor Pep58X fused with the RNA binding protein MS2CP. The fusion polypeptide is designated "MS2CP-Pep58X". In the lower part of the Figure, a target messenger RNA is

Art Unit: 1654

shown comprising a target nucleotide motif of the RNA binding protein MS2CP, which has been designated "MS2" and which is shown in the Figure by a stem-loop structure and an expression cassette of the target protein of interest. As shown in the Figure, the fused protein MS2CP makes possible the binding of the fusion polypeptide to the target messenger RNA at the level of the MS2 site, and this enables the peptide inhibitor Pep58X to exert its inhibitory biological activity specifically on the target messenger RNA.

[0024] FIG. 2 is a diagram showing the map of the plasmid pMS2CP-Pep58X. On the vector, "CMV" designates the promoter of the cauliflower mosaic virus which controls the expression of the open reading frame coding for the fusion polypeptide between the RNA binding protein MS2CP and the peptide inhibitor Pep58X. In the Figure, the open reading frame codes for a fusion polypeptide in which the protein MS2CP and the peptide inhibitor Pep58X are separated by the peptide HA (sequence "YPYDVPDYA" [SEQ ID N.sup.o11] extending from amino acid 98 to amino acid 106 of the protein hemagglutinin HA1), which constitutes a label for the detection and purification of the fusion polypeptide. "T7" designates the promoter of the phage T7, which makes possible RNA synthesis in vitro.

[0029] In the Figure, the bidirectional promoter CMV controls the expression of two open reading frames, (i) an open reading frame coding for luciferase R ("Luc R") and including a region 3'UTR containing eight copies of the nucleotide site MS2, a recognition site of the protein MS2CP and (ii) an open reading frame coding for the protein luciferase F ("LucF"), respectively.

[0106] In fact, it has been shown according to the invention that a fusion polypeptide between the peptide Pep58X of sequence SEQ ID N.sup.o 1 and the RNA binding protein MS2CP was capable of inhibiting specifically the translation of a messenger RNA comprising the target nucleotide site MS2 and an open reading frame coding for the marker protein luciferase, placed under the control of a suitable promoter.

[0107] As illustrated in FIG. 1, the protein MS2CP contained in the fusion polypeptide binds selectively to its target nucleotide site MS2, and this enables the peptide inhibitor Pep58X to specifically inhibit the expression of the messenger RNA or messenger RNAs containing the target nucleotide site MS2.

[0108] The same results have been reported by the applicant with a fusion polypeptide containing the peptide inhibitor Pep58H and the RNA binding protein MS2CP.

Art Unit: 1654

[0109] In a fusion polypeptide according to the invention, the RNA binding protein, which is fused with the peptide inhibitor of the translation of proteins defined above is selected preferably from MS2CP, N, IRP and U1A, listed in Table 1 below. TABLE-US-00001 TABLE 1 Preferred binding proteins

Binding protein Reference MS2 J. Collier, N, Gray, M. Wickens, Genes Dev. 12 (1998) 3226-3235. Witherell, G., J. Gott, and O. Uhlenbeck. 1991. Specific interaction between RNA phage coat proteins and RNA. Prog. Nucleic Acids Res. Mol. Biol. 40: 185-220 N E. De Gregorio, T. Preiss, M. W. Hentze, EMBO J. 18 (1999) 4865-4874. Tan, R. & Frankel, A. D. (1994) Biochemistry 33, 14579-14585 IRP E. De Gregorio, J. Baron, T. Preiss, M. Hentze, RNA 7 (2001) 106-113. Hentze M W; Kuhne L C. Proc Natl Acad Sci USA. 1996 Aug. 6; 93(16): 8175-82. Review. PMID: 8710843 U1A A. S. Brodsky, P. A. Silver, RNA 6 (2000) 1737-1749.

[0120] Specific and illustrative examples of specific inhibitory fusion polypeptides according to the invention are constituted by: [0121] fusion polypeptide MS2CP-HA TAG-Pep58X of amino acid sequence SEQ ID NO: 5, which is encoded in the nucleic acid of sequence SEQ ID NO: 7. [0122] fusion polypeptide MS2CP-HA TAG-Pep58H of amino acid sequence SEQ ID NO: 6, which is encoded in the nucleic acid of sequence SEQ ID NO: 8.

[0124] The preferred nucleic acids according to the invention are the following: [0125] the nucleic acid of sequence SEQ ID NO: 7 coding for the fusion polypeptide MS2-HA TAG-Pep58X; [0126] the nucleic acid of sequence SEQ ID N.sup.o8 coding for the fusion polypeptide MS2CP-HA TAG-Pep58H.

[0175] A preferred vector comprising the nucleic acid containing (i) at least one copy of a target nucleotide sequence of the RNA binding protein contained in the specific inhibitory fusion polypeptide and (ii) the polynucleotide of interest, the control of the translation of which is desired is the vector pRLucLuc-CMVin+3'UTRGb (MS2)u, which is described in the examples.

Construction Protocol for the Recombinant Vectors MS2CP-Pep58X and MS2CP-Pep58H

[0231] The amplimers corresponding to Pep58X and Pep58H obtained by using as matrix respectively the plasmid pT7TSEDENBP (oligonucleotides ATGCTAGCGTAAAGTTCGACAGACTCAGAAAG [SEQ ID N 12] and ATGCGGCCGCTGCATTGAGCTGCTGCATTGTC) [SEQ ID N.sup.o13] and the plasmid pT7TSCUGBP (oligonucleotides ATGCTAGCGTAAAATTTGCTGATACACAGMG [SEQ ID N.sup.o14] and ATGCGGCCGCTGCGCTGATTTGCTGCATCTGC [SEQ ID N.sup.o15]) (Paillard, 2002) are digested with NheI and XhoI and inserted into the vector pMS2CP-HA digested

Art Unit: 1654

beforehand with NheI and XhoI. The vector pMS2CP-HA was obtained by insertion of the tag HA (TACCCATACGATGTTCCAGATTACGCT [SEQ ID N.sup.o16]) into the vector pcNMS2 (Lykke Andersen, Cell (103) 1121-31).

Functional Characterisation of the Specific Inhibitory Fusion Polypeptide MS2CP-Pep58X in Mammalian Cells Ex Vivo

[0241] The quantity of fusion proteins produced was evaluated by Western blot (anti HA polyclonal antibody, Santa Cruz Biotechnology) and standardised with respect to the quantity of a ubiquitous cell protein, the protein PCNA (Anti-Proliferating Cell Nuclear Antigen (PCNA) monoclonal antibody, Sigma Aldrich Company). The Luc F mRNA does not contain an MS2 site in its untranslated 3' part and should not be affected by the expression of MS2CP-Pep58X. In order to verify this, the expression of Luc F in the presence of MS2PC-Pep58X is analysed by the calculation $d(\text{LucF})/d(\text{concentration of } \text{MS2CP-Pep58X})$.

[0242] The results are presented FIG. 7A. The slope of the straight line obtained is close to one (0.998), confirming that the fusion protein produced does not affect the expression of luciferase F. The expression of Luc F was then used as internal standard to estimate the effect of the fusion protein on the translation of Luc R mRNA. This latter contains, in fact, in its untranslated 3' part the MS2 sites permitting the binding of the protein MS2CP-Pep58X.

[0243] The results were analysed by the calculation $d(R/F)/d(\text{concentration of } \text{MS2CP-Pep58X})$ (FIG. 7B). The experiment was performed in parallel with MS2CP, the values obtained with MS2CP correspond to one hundred percent expression of Luc R.

[0245] The expression of MS2CP-Pep58X causes a repression of the translation of Luc R mRNA, the slope of the corresponding straight line is about -0.6 (FIG. 7B). The applicant has shown that the system of analysis also permits the study of proteins which stimulate translation (results not shown).
TABLE-US-00002
TABLE 2 Preferred systems of inducible regulation
COMMERCIAL OR NAME PROMOTER INDUCER LITERATURE REFERENCE
pMSG MMTV-LTR Dexamethasone Amersham
Pharmacia ("mouse mammary tumor virus") pOPRSVI/MCS RSV-LTR IPTG Stratagene
<< Rous sarcoma virus >> pTet-Splice Tet Tetracycline Life Technologies
pTRE hCMV-1 Tetracycline or Clontech doxycycline pRev-TRE hCMV-1 Tetracycline or Clontech doxycycline .sup.2pRetro-On hCMV-1 Tetracycline or Clontech pRetro-Off doxycycline pIND series .DELTA.HSP Ecdysone Invitrogen ("Heat shock protein") pPOP mPGK/lacO IPTG G. N. Hannan, S. A. Lehnert,

Art Unit: 1654

(phosphoglycerate kinase) E. S. MacAvoy, P. A. Jennings and P. L. Molloy, An engineered PGK promoter and lac operator- repressor system for the regulation of gene expression in mammalian cells. *Gene* 130 (1993), pp. 233-239. pEF-LAC hEF-1.alpha./lacO IPTG Edamatsu, H., Kaziro, Y., and Itoh, H. (1997) Inducible high level expression vector for mammalian cells, pEF-LAC carrying human elongation factor 1.alpha. promoter and lac operator. *Gene* 187, 289-294. pBPVMT1 mMT-I (metallothionein I) Cd.sup.++, Zn.sup.++, PMA.sup.++ Pavlakakis, G. N., and Hamer, D. H. (1983) Regulation of a metallothionein-growth hormone hybrid gene in bovine papilloma virus. *Proc. Natl. Acad. Sci. USA* 80, 397-401 pMT hMT-II (metallothionein II) Cd.sup.++, Zn.sup.++, PMA.sup.++ Friedman, J. S., Cofer, C. L., Anderson, C. L., Kushner, J. A., Gray, P. P., Chapman, G. E., Stuart, M. C., Lazarus, L., Shine, J., and Kushner, P. J. (1989) High expression in mammalian cells without amplification. *Bio/Technology* 7, 359-362 pMT302 hMT-IIA (mutant) Cd.sup.++, Zn.sup.++, Makarov, S. S., Jonat, C., PMA.sup.++ and Haskill, S. (1994) Hyperinducible human metallothionein promoter with a low level basal activity. *Nucleic Acids Res.* 22 1504-1505 pIPF hIFN-.alpha., (interferon .alpha.) Virus Mori, T., Yamamoto, K., Ohta, T., Sakamoto, C., Sato, M., Koide, K., Murakami, T., Fujii, M., Fukuda, S., and Kurimoto, M. (1994) A high level and regulatable production system for recombinant glycoproteins using a human interferon-.alpha. promoter-based expression vector. *Gene* 144 289-293 pGRE5 5XGRE/Ad2MLP Dexmethasone Mader, S., and White, J. H. "(glucocorticoid response (1993) A steroid-inducible element/adenovirus major promoter for the controlled late promoter") overexpression of cloned genes in eukaryotic cells. GRE5 "high affinity Dexmethasone S. Mader and J. H. White, A glucocorticoid response element steroid-inducible promoter for (GRE)/Adenovirus 2MLP" the controlled overexpression of cloned genes in eukaryotic cells. *Proc. Natl. Acad. Sci. USA* 90 (1993), pp. 5603-5607 0(12) 5603-7 pRDB "DRE/MMTV TTCD". A. De Benedetti and R. E. (dioxin response element)" Rhoads, A novel BK virus-based episomal vector for expression of foreign genes in mammalian cells. *Nucleic Acids Res.* 19 (1991), pp. 1925-1931.

[0246] TABLE-US-00003 TABLE 3 SEQ ID N.degree. Designation Type 1 Pep58X aa peptide 2 Pep 58H aa peptide 3 EDEN-BP (aa84-155) peptide 4 CUG-BP (aa155-242) peptide 5 Fusion MS2CP-HA TAG-Pep58X peptide 6 Fusion MS2CP-HA TAG-Pep58H peptide 7 Fusion MS2CP-HA TAG-Pep58X nucleic acid 8 Fusion MS2CP-HA TAG-Pep58H nucleic acid 9 EDENBP peptide 10 EDENBP nucleic acid 11 Peptide HA peptide 12 Primer nucleic acid 13 Primer nucleic acid 14 Primer nucleic acid 15 Primer nucleic acid 16 Peptide HA nucleic acid

8. Fusion polypeptide according to claim 7, characterised in that the RNA binding protein is selected from MS2CP, N. IRP and U1A.

Thus, neither the claims nor the specification adequately describe the claimed genus the “fusion polypeptide” (claims 7-8 and 37), because a specific **RNA binding protein** genus of proteins has not been adequately described, beyond the **4 species of: MS2CP, N, IRP and UIA (claim 8)**, as to what other RNA binding protein(s) Applicant held “possession” of at the time of the invention, as constituting the invention. With the substantial variability among the broad genus, contemplating any RNA binding protein, it is not clear as to which one or more of this assumedly broad genus, OR whether any other RNA binding proteins are even known? One of skill in the art would not recognize from the disclosure that the Applicant was in possession of such a genus, namely any “RNA binding protein” and thus any “fusion polypeptide” as claimed, other than the 4 RNA binding peptides capable of being bound to the elected SEQ ID NOS: 5-6 to create the claimed “fusion polypeptides” of the invention.

NOTE: The Examiner does not equally make an enablement rejection, as it is deemed that one ordinary skill in the art COULD find and conjugate, without undue experimentation, RNA binding proteins of interest in order to enable such a fusion protein, as claimed. The issue is that the present description is not found to adequately 'describe' the genus of any RNA binding protein(s) Applicant had “possession” of at the time of the invention, in order to carry out the invention as claimed.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MAURY AUDET whose telephone number is (571)272-0960. The examiner can normally be reached on M-Th, 7AM-5:30PM (10 Hrs.).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
MA, 1/31/2009

/Maury Audet/
Examiner, Art Unit 1654